The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases

Hannan, Fadil M ORCID: 0000-0002-2975-5170, Kallay, Enikoe, Chang, Wenhan, Brandi, Maria Luisa and Thakker, Rajesh V (2018) The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. NATURE REVIEWS ENDOCRINOLOGY, 15 (1). pp. 33-51.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1038/s41574-018-0115-0

Abstract

The Ca2+-sensing receptor (CaSR) is a dimeric family C G protein-coupled receptor that is expressed in calcitropic tissues such as the parathyroid glands and the kidneys and signals via G proteins and β-arrestin. The CaSR has a pivotal role in bone and mineral metabolism, as it regulates parathyroid hormone secretion, urinary Ca2+ excretion, skeletal development and lactation. The importance of the CaSR for these calcitropic processes is highlighted by loss-of-function and gain-of-function CaSR mutations that cause familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia, respectively, and also by the fact that alterations in parathyroid CaSR expression contribute to the pathogenesis of primary and secondary hyperparathyroidism. Moreover, the CaSR is an established therapeutic target for hyperparathyroid disorders. The CaSR is also expressed in organs not involved in Ca2+ homeostasis: it has noncalcitropic roles in lung and neuronal development, vascular tone, gastrointestinal nutrient sensing, wound healing and secretion of insulin and enteroendocrine hormones. Furthermore, the abnormal expression or function of the CaSR is implicated in cardiovascular and neurological diseases, as well as in asthma, and the CaSR is reported to protect against colorectal cancer and neuroblastoma but increase the malignant potential of prostate and breast cancers.

Item Type:	Article
Uncontrolled Keywords:	Humans, Hypercalcemia, Hypocalcemia, Hypoparathyroidism, Genetic Predisposition to Disease, Receptors, Calcium-Sensing, Prognosis, Treatment Outcome, Incidence, Risk Assessment, Gene Expression Regulation, Mutation, Female, Male, Nephrolithiasis, Hypercalciuria, Calcimimetic Agents
Depositing User:	Symplectic Admin
Date Deposited:	27 Aug 2019 10:20
Last Modified:	19 Jan 2023 00:28
DOI:	10.1038/s41574-018-0115-0
Open Access URL:	https://www.ncbi.nlm.nih.gov/pubmed/30443043
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3052639